cyclophosphamide for remission induction in a randomized controlled trial Cyclophosphamide (dosing provided in Table 1 Recommendation: In patients with GPA/MPA with active glomerulonephritis, we conditionally recommend against the routine addition of plasma exchange to remission induction therapy. Plasma exchange should not be initiated in all patients with active glomerulonephritis but can be considered for patients at higher risk of progression to end-stage renal disease (ESRD) who accept a